Response Assessement of Lutetium-177-PSMA-Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer

• Conditions: C61; Malignant neoplasm of prostate

• Registration Number: DRKS00013665
• Lead Sponsor: niversitätsklinikum Freiburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-12-28
• Study Completion: 2021-09-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 126

Inclusion Criteria

patients treated with Lutetium-177-PSMA-Targeted Radionuclide Therapy in the Department of nuclear medicine Universitätsklinikum Freiburg btween 07/15 and 12/17.

Exclusion Criteria

patients for whom sufficient data acquisition could not be accomplished

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evaluation of serologic and imaging response to Lutetium-177-PSMA-Targeted Radionuclide Therapy

Secondary Outcome Measures

Name	Time	Method
assessement of clinical response to Lutetium-177-PSMA-Targeted Radionuclide Therapy (pain, quality of life)